Tenax Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$52.6MTTM through 30 Jun 2026
Free Cash Flow -$46MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-54.2%ROE
-50.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio14.56x
Net Debt-$97.6Mnet cash position
Cash & Equivalents$118M
Quality Metrics
Altman Z-Score0.37
Piotroski F-Score2 / 9
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $0
Diluted EPS-$1.48TTMFY2025: $-1.34
Dividend
No dividend
Capital Allocation
R&D Spend$45.3M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Cardiovascular and Pulmonary Therapeutics | $0 | 0.0% | View detailsTopline data from the Phase 3 LEVEL trial is expected in Q3 2026, and LEVEL-2 enrollment is anticipated to complete by the end of 2027. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.